Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years

    August 21, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

    August 21, 2026
    Facebook X (Twitter) Instagram
    Arab BulletinArab Bulletin
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Arab BulletinArab Bulletin
    Home » Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk’s New York
    PR Newswire

    Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk’s New York

    August 17, 2026
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    NEW YORK, Aug. 17, 2026 /PRNewswire/ — Mavrix, the global data acquisition and research execution company, used its Platinum Sponsorship of The Quirk’s Event New York 2026 to advance a clear view on the changing research landscape: as artificial intelligence makes data generation and analysis faster and more accessible, the ability to reach, verify and engage the right real people is becoming more valuable, not less.

    Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk’s New York

    Held July 29–30 at the Javits Center, Mavrix participated in two featured sessions, first with Delineate and then with Boston Consulting Group (BCG) and Knit.

    In ‘Free Data, Worthless Data: What’s Actually Left Worth Paying For,’ Mavrix and Delineate examined how AI is automating survey creation, coding, summarization, analysis and reporting. The session’s central argument was that as routine production becomes easier to automate, value shifts toward evidence that is harder to replicate: proprietary and timely signals, verified human participation, hard-to-reach audiences and judgment about what matters.

    “AI gives our industry extraordinary capabilities,” said Glen Collins, EVP, Global Commercial Group at Mavrix. “But AI cannot fix speaking to the wrong people. If the human evidence underneath is weak, technology simply allows us to analyze weak evidence faster and with greater confidence. Better human evidence in means better intelligence out.“

    Mavrix also described verification as a Human Evidence Chain: Reach, Qualify, Verify, Engage and Defend. The objective is not more checks, but evidence that can withstand scrutiny when findings are challenged.

    On Day 2 of the Quirk’s conference, Mavrix joined BCG and Knit to discuss Qual-at-Scale, examining how AI moderation, video and analysis can enable richer participant conversations at greater speed and scale. For Mavrix, a key implication is that participant eligibility alone is no longer enough. Richer tasks require people who are relevant, articulate, engaged, authentic and ready to contribute.

    Across both sessions, Mavrix’s message converged around three factors: speed, quality and AI. Speed makes research timely enough to influence a decision. Quality makes the evidence worth acting on. AI helps surface patterns at previously impractical scale.

    Mavrix also reinforced a broader principle: the audience should determine the recruitment method, not the other way around. Online, telephone, specialist communities, face-to-face and mixed methods may all be appropriate depending on the audience and market.

    For more information, visit www.mavrixdata.com

    Media Contact
    media@mavrixdata.com 

    Mavrix Logo

    Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/mavrix-makes-the-case-for-trusted-human-evidence-in-the-ai-era-at-quirks-new-york-302852901.html

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email

    Related Posts

    PR Newswire August 21, 2026

    Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years

    PR Newswire August 21, 2026

    STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

    PR Newswire August 21, 2026

    Hisense Unveils 2026 E8S ULED MiniLED TV Models with Exclusive Amazon Launch Deals

    PR Newswire August 21, 2026

    5 Back to School Wellness Heroes for the Bright Minds of Tomorrow

    PR Newswire August 20, 2026

    Wizzmoni Partners with Oman Air to Launch AI-Powered Co-Branded ‘Wizz Voyager’ Multi-Currency Travel Card

    PR Newswire August 20, 2026

    Apollo Hospitals launches ‘Always Open, Always Here’, a global first in healthcare from India

    Latest News
    Business August 20, 2026

    Wall Street rises after Treasury expands debt buybacks

    Healthcare shares strengthen market gains
    Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026
    © 2026 Arab Bulletin | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.